STUDY. Clinical Significance of Skin Biopsies in the Diagnosis and Management of Graft-vs-Host Disease in Early Postallogeneic
|
|
- Georgiana Cook
- 5 years ago
- Views:
Transcription
1 STUDY Clinical Significance of Skin Biopsies in the Diagnosis and Management of Graft-vs-Host Disease in Early Postallogeneic Bone Marrow Transplantation Youwen Zhou, MD, PhD; Michael J. Barnett, BM, FRCP; Jason K. Rivers, MD, FRCPC Objective: To determine the value of skin biopsies in the management of suspected graft-vs-host disease (GVHD) within 30 days of allogeneic bone marrow transplantation (BMT). Design: Retrospective study based on review of a BMT database. Setting: Leukemia/BMT ward of a tertiary care, university teaching hospital. Patients: One hundred and eighty-seven consecutive patients who received allogeneic BMT between January 1, 1994, and June 30, 1997, at Vancouver General Hospital, Vancouver, British Columbia. Main Outcome Measures: (1) Skin biopsy frequency for patients with rashes suggestive of acute GVHD; (2) clinical significance of skin biopsy in the management of patients with suspected acute GVHD after BMT; (3) relationship between severity of clinical GVHD and the likelihood to receive GVHD therapy; and (4) relationship between biopsy status or biopsy result and outcome of BMT (acute and chronic GVHD, transplant-related mortality, and overall and event-free survival). Results: During the early post-bmt period ( 30 days after BMT), 88 patients had rashes suggestive of acute GVHD; of these, 51 (58%) underwent skin biopsy to confirm the diagnosis. Skin biopsies were performed more often for higher clinical stages of cutaneous GVHD. There was no significant difference between the patients with positive biopsy findings and those with negative findings, either in the clinical severity of acute GVHD or in likelihood to receive treatment for GVHD. Most (85%) of the patients who underwent biopsies and received GVHD therapy had treatment initiated before skin biopsies were performed or before the results were available. The higher the clinical grade of overall acute GVHD, the more likely it was that the patients were treated for GVHD (P.001). The outcome of BMT was not influenced by the skin biopsy status or biopsy result. Conclusions: The biopsy findings correlated poorly with the clinical severity of skin rash suggestive of acute GVHD soon after BMT. The decision to treat suspected acute GVHD depended not on skin biopsy findings but rather on clinical severity of acute GVHD. In this regard, skin biopsy has a limited role in the management of patients early after allogeneic BMT. Arch Dermatol. 2000;136: From the Divisions of Dermatology (Drs Zhou and Rivers) and Hematology (Dr Barnett), Department of Medicine, Vancouver General Hospital and University of British Columbia, Vancouver. GRAFT-VS-HOST disease (GVHD) after allogeneic bone marrow transplantation (BMT) is an immunological process in which activated donor lymphocytes mount an attack on recipient tissues. This process involves secretion of cytokines and recruitment of additional inflammatory cells. The severity of acute GVHD is one of the most important prognostic factors that predict outcome of BMT. 1 The likelihood of developing acute GVHD (ie,within 100 days of BMT) depends on a number of factors, including the degree of histoincompatibility, number of T lymphocytes in the graft, patient s age, and the prophylactic immunosuppressive regimen used. 2-5 Clinically relevant acute GVHD occurs in 35% to 50% of patients given HLA-identical marrow grafts. 1 The skin is often the initial organ to manifest acute GVHD. 1,6 Clinically, acute cutaneous GVHD is characterized by a maculopapular rash that involves the palms and soles and, as the disease progresses, the upper trunk, neck, cheeks, and ears. 1,2,6 For editorial comment see page 779 In addition to the skin, the liver and gastrointestinal system are often involved in acute GVHD. 1 As summarized 717
2 PATIENTS AND METHODS DATABASE A BMT database is maintained by the Leukemia/BMT Program of British Columbia at Vancouver General Hospital. For each patient undergoing BMT, the following information is recorded with regard to acute GVHD of the skin, liver, and gut: onset, clinical stage, date and result of biopsies, and therapeutic interventions. In addition, clinical outcome variables are recorded, including (1) peak cutaneous and overall clinical severity of acute GVHD; (2) development of chronic GVHD (limited vs extensive); (3) mortality due to GVHD; and (4) mortality due to other causes such as infection, graft failure, regimen-related toxic effects, and relapse of malignancy. A widely used clinical staging/grading system 8 is used for the construction of the database and is summarized in Table 1 and Table 2. POLICY FOR DIAGNOSIS AND TREATMENT OF ACUTE GVHD The diagnosis of acute GVHD (ie, within 100 days of BMT) was based on clinical symptoms and signs as well as the results of tests (ie, liver function, endoscopy, and skin, gut, or liver biopsies). There was no specific guideline to indicate when a skin (or other) biopsy should be carried out, although histologic confirmation of the diagnosis was obtained routinely. Primary treatment of established acute GVHD was with corticosteroids and started within 12 hours of the diagnosis. Once initiated, the duration of treatment was for a minimum of 6 weeks and did not depend on the results of diagnostic tests. Similarly, cyclosporine was generally continued for 3 to 4 months (related donor) or 6 months (unrelated donor) after BMT and then, if the GVHD was quiescent, tapered over a few weeks. The exception to this wasforpatientsdeemedtobeathighriskforrelapse, forwhom the cyclosporine therapy was discontinued earlier. STUDY DESIGN Patients who developed skin rashes before day 30 after BMT were placed into 1 of 2 groups: those undergoing biopsy and those not. The group undergoing biopsy was divided into 2 subgroups, patients with positive skin biopsy findings and those with negative findings. A positive biopsy finding was recorded when the pathology report stated diagnostic for GVHD if no histologic grade, or a grade of 2 or higher, was given. The patients were also divided into treated and nontreated groups. Treatment was defined as initiation of anti-gvhd therapy at or after the first clinical diagnosis of acute GVHD. The following parameters were then analyzed for each patient category: (1) clinical severity of GVHD (skin and overall) at the time of first diagnosis; (2) the skin biopsy frequency; (3) biopsy result; (4) initiation of anti-gvhd therapy as a result of the diagnosis of GVHD; and (5) the BMT outcome (acute and chronic GVHD, transplantrelated mortality, and overall event-free survival). STATISTICAL ANALYSIS We used 2 and t tests where appropriate to calculate the statistical significance of the GVHD findings. Survival analysis using the Kaplan-Meier method was performed to estimate overall and event-free survival (with death or relapse as events) and the actuarial probabilities of transplantrelated mortality and GVHD. in Table 1 and Table 2, acute GVHD can be graded according to its clinical severity. 1,2,7,8 Outcome analyses have established the prognostic value of this staging system in that the higher the overall clinical grade, the higher the transplant-related mortality. 1,9,10 Skin biopsies are frequently used to confirm the clinical diagnosis of acute GVHD. Histologically, acute GVHD of the skin is characterized by varying degrees of damage to the epidermal keratinocytes In grade 1, vacuolization of the basal keratinocytes is present; in grade 2, both basal keratinocyte vacuolization and dyskeratotic keratinocytes are present; in grade 3, focal clefting of the basal layer is formed; and in grade 4, the epidermis is totally separated from the underlying dermis. The interpretation of skin biopsy results after BMT can be difficult, however, because similar histologic findings may result from the high-dose chemotherapy/radiotherapy of the preparatory regimen before transplantation or other drug treatment afterwards. 17,19-21 The situation is further complicated by the fact that frequently there is a lack of correlation between clinical features and histologic findings. 16,17 For example, the skin in a clinically affected area may seem unremarkable histologically, or clincally uninvolved skin can display basal keratinocyte vacuolization and necrosis consistent with well-established GVHD. 17 Therefore, the diagnostic value of skin biopsies has been questioned Several investigators have studied the prognostic value of skin biopsy findings after BMT. 18,21 In 1 report, dyskeratotic keratinocytes, number of exocytosed lymphocytes, and presence of follicular involvement did not correlate with outcome. 18 In another, more recent study, no significance was found in any of the skin histologic parameters analyzed, including necrotic (dyskeratotic) keratinocytes, basal vacuolization, satellitosis, and appendageal involvement. 21 These studies suggest that skin biopsies are of little prognostic value. Despite these controversies, skin biopsies are still performed regularly on patients after BMT, sometimes as rush specimens. 22 To our knowledge, there have been few studies to define the role, if any, of skin biopsies in the management of such patients. A retrospective review of data from a leukemia/bmt ward between 1994 and 1997 was performed to determine the frequency and clinical utility of skin biopsies within 30 days of BMT in the management of patients with suspected GVHD. 718
3 Table 1. Clinical Staging of Acute Graft-vs-Host Disease Stage Skin Liver Gut 1 Maculopapular rash 25% BSA* Bilirubin, µmol/l ( mg/dl) Diarrhea L/d or persistent nausea (± vomiting) with positive gut biopsy findings 2 Maculopapular rash 25%-50% BSA Bilirubin, µmol/l ( mg/dl) Diarrhea L/d 3 Maculopapular rash 50% BSA Bilirubin, µmol/l ( mg/dl) Diarrhea 1.5 L/d 4 Generalized erythema with bullous formation and/or desquamation Bilirubin, 255 µmol/l ( 14.9 mg/dl) Severe abdominal pain or ileus *BSA indicates body surface area. Table 2. Overall Clinical Grading of Acute Graft-vs-Host Disease Grade Skin Stage Liver Stage Gut Stage I (Mild) 1 to II (Moderate) 3* or 1 or 1 III (Severe) 0 to 3, and 2 to 3 or 2 to 4 IV (Life threatening) 4 or 4, or 0 to 4 plus 4 of skin or liver *Skin stage 3 alone is considered overall grade II. RESULTS PATIENT POPULATION PROFILE A total of 187 patients underwent allogeneic BMT between January 1, 1994, and June 30, 1997, at Vancouver General Hospital. Relevant information was available on all patients. In the early period after BMT (ie, within 30 days), 88 patients developed a rash suggestive of acute GVHD. The analysis centers on these patients. There were 54 men and 34 women, with a median age of 40 years (range, years). The indications for BMT were as follows: chronic myeloid leukemia (n=21), acute myelogenous leukemia (n=21), myelodysplastic syndrome (n=13), multiple myeloma (n=10), acute lymphoblastic leukemia (n=9), non-hogkin lymphoma (n=9), and other (n=5). The source of marrow was as follows: unrelated donor (n=48), HLA-matched sibling (n=39), and mismatched sibling (n=1). Prophylaxis for GVHD was with cyclosporine and methotrexate (n=69) or T-cell depletion of the allograft and cyclosporine (n=19). BIOPSY FREQUENCY Eighty-eight patients developed skin rashes suggestive of acute GVHD within 30 days of BMT, and 51 (58%) of them underwent skin biopsy to confirm the diagnosis. The average clinical cutaneous stages and overall grades of acute GVHD are given in Table 3. The mean±sem skin stage (1.71±0.18) and overall grade (2.02±0.12) of the group undergoing biopsy did not differ significantly from that of the group not undergoing biopsy (1.41±0.11 and 1.84±0.12, respectively; P.05, t test). All patients with skin stage 4 (n=2) and 10 of 13 patients with stage 3 GVHD underwent biopsy, while the biopsy rates for stages 1 and 2 were lower (44% and 67%, respectively). The group undergoing biopsy was more likely to receive GVHD treatment than the group without biopsy (80% vs 57%; P.02, 2 analysis [Table 3]). CLINICAL CORRELATION OF SKIN BIOPSY RESULTS The results of skin biopsy were positive in 27 patients and negative in 24. As outlined in Table 4, the 2 subgroups did not differ in their average clinical severity of acute GVHD, either in skin-specific stages or in overall grades. The percentage of positive biopsy findings for stages 3 and 4 (50%) was no higher than the lower clinical stages of cutaneous GVHD (57% and 52%, respectively). More importantly, the patients with positive or negative biopsy findings did not differ in their likelihood to receive GVHD treatment. Specifically, 85% of the patients with a positive biopsy finding received anti- GVHD therapy compared with 75% of the patients with a negative finding (P.05, 2 analysis). TEMPORAL RELATIONSHIP BETWEEN SKIN BIOPSY AND INITIATION OF GVHD THERAPY Of the 51 patients who underwent skin biopsy, 41 received treatment for GVHD. However, in most of the treated cases, therapy began before the biopsy results were available (29 patients) or even before biopsies were performed (7 patients). The biopsy results were available for only 5 patients at the time of therapy initiation. For 3 of these 5 patients, the therapy was initiated when there was clinical deterioration of the GVHD (1 with new development of diarrhea and 2 with worsening of skin GVHD from stage 1 or 2 to stage 3 or 4). Only 2 patients (3%) received treatment for GVHD after (presumably because of) positive skin biopsy findings in the absence of other independent indications for GVHD therapy. Both patients had histologic grade 2, clinical stage 2 skin GVHD and overall grade I GVHD when the therapy was initiated. RELATIONSHIP BETWEEN CLINICAL SEVERITY OF GVHD AND THERAPEUTIC INTERVENTION Sixty-two of the 88 patients with skin rashes before day 30 following BMT received treatment for GVHD around the time of diagnosis. Patients in the treated group, compared with the nontreated group, had significantly higher skin GVHD stages (1.67±0.10 vs 1.35±0.12; P.05) and 719
4 Table 3. Clinical Parameters According to Biopsy Status* Biopsy (n = 51) No Biopsy (n = 37) P Skin GVHD stage 1.71 ± ± Overall GVHD grade 2.02 ± ± Patients treated, No. (%) 41 (80) 21 (57).02 *Unless otherwise indicated, data are. GVHD indicates graft-vs-host disease. P value calculated using 2 analysis. Table 4. Clinical Parameters According to Biopsy Result* Positive (n = 27) Negative (n = 24) P Skin GVHD stage 1.70 ± ± Overall GVHD grade 2.00 ± ± Patients treated, No. (%) 23 (85) 18 (75).05 *Unless otherwise indicated, data are. GVHD indicates graft-vs-host disease. P value calculated using 2 analysis. Table 5. Outcome of Bone Marrow Transplantation According to Skin Biopsy Status* Biopsy (n = 51) No Biopsy (n = 37) P Peak clinical severity 2.16 ± ± of skin acute GVHD, Peak clinical severity 2.83 ± ± of overall acute GVHD, Acute GVHD (grade II-IV) 85 (79-93) 76 (61-88).05 Chronic GVHD 73 (57-87) 79 (62-92).97 Transplant-related mortality 48 (35-63) 41 (27-60).31 Event-free survival 33 (21-46) 43 (27-58).20 Overall survival 35 (23-48) 46 (30-61).20 *Unless otherwise indicated, data are actuarial probabilities in percentages (95% confidence interval). P value calculated using Kaplan-Meier analysis. overall GVHD grades (2.19±0.10 vs 1.35±0.10; P.001). Indeed, all patients with overall III (n=16) and IV (n=3) GVHD grades were treated. Most of the overall grade II patients (79%; n=42) also received GVHD therapy. In contrast, only 37% of the patients with mild clinical overall GVHD (grade I, n=27) received GVHD therapy. OUTCOME OF BMT ACCORDING TO BIOPSY STATUS AND RESULT The peak clinical severity of acute GVHD before day 100 post-bmt was analyzed according to whether a skin biopsy was performed and, if so, according to the biopsy findings (Table 5 and Table 6). In addition, actuarial probabilities of acute (at 100 days) and chronic (at 1 year) Table 6. Outcome of Bone Marrow Transplantation According to Skin Biopsy Result* Positive (n = 27) GVHD, transplant-related mortality (at 3 years), and eventfree and overall survival (at 3 years) for the patient groups are given. There was no statistically significant difference in any of the outcomes analyzed. COMMENT Negative (n = 24) P Peak clinical severity 2.37 ± ± of skin acute GVHD, Peak clinical severity 2.56 ± ± of overall acute GVHD, Acute GVHD (grade II-IV) 86 (70-96) 83 (66-95).9 Chronic GVHD 82 (61-95) 61 (38-85).05 Transplant-related mortality 43 (27-64) 53 (34-75).62 Event-free survival 41 (23-58) 25 (10-43).43 Overall survival 44 (26-62) 25 (10-43).29 *Unless otherwise indicated, data are actuarial probabilities in percentages (95% confidence interval). GVHD indicates graft-vs-host disease. P value calculated using Kaplan-Meier analysis. In this retrospective study we set out to determine the frequency and clinical utility of skin biopsy within 30 days of allogeneic BMT in the management of patients with a suspicious rash. We found that more than half of patients suspected to have skin GVHD underwent skin biopsy to confirm the diagnosis, and that the biopsy rates were related to clinical severity of the rash, with moderate to severe rashes more likely to be tested. The biopsy findings, however, did not correlate with the clinical severity of skin and overall GVHD, nor did they have any impact on the likelihood for the patients to receive GVHD therapy. Furthermore, the outcome of BMT was not influenced by whether a biopsy was done or by the result. Most patients undergoing biopsy who were treated for GVHD had therapy initiated before the biopsy was performed or before the results were available. Indeed, skin biopsy findings were the reason for initiation of GVHD therapy in only 3% of all treated patients. In our patient population, the decision to treat GVHD was dependent on clinical severity of the GVHD rather than on the skin biopsy findings. Similar results were recently reported by another group of investigators who demonstrated that rush skin biopsies did not have any clinically significant relevance in the management of patients with GVHD after BMT. 22 Specifically, of 36 biopsy specimens processed on an urgent basis, only 2 resulted in an immediate change in management. In summary, skin biopsy findings within 30 days of allogeneic BMT do not correlate with clinical severity of GVHD, and skin biopsy seems to play only a minor role in directing a physician to initiate therapy for acute GVHD. Therefore, we suggest that the routine practice of sub- 720
5 jecting patients to such biopsies could be abandoned without compromising their care. Accepted for publication December 22, Presented in part at Resident s Forum, American Academy of Dermatology annual meeting, New Orleans, La, March 21, We would like to thank Daphne Brockington, CCHRA[C] and Janet Nitta, CCHRA[C], for assistance in searching the BMT Database and performing the bone marrow transplantation outcome analysis. Reprints: Jason K. Rivers, MD, FRCPC, 835 West 10th Ave, Vancouver, British Columbia, V5Z 4E8, Canada ( jrivers@interchange.ubc.ca). REFERENCES 1. Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Ann Rev Med. 1984;35: Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versushost disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1984;18: Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313: Vogelsang GB, Hess AD, Santos GW. Acute graft-versus-host disease: clinical characteristics in the cyclosporin era. Medicine. 1989;67: Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graftversus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graftvs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY: Marcel Dekker. 1990: Saurat JH. Cutaneous manifestations of graft-versus-host disease. Int J Dermatol. 1981;4: Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation. N Engl J Med. 1995;292: Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15: Storb R, Prentice RL, Sullivan KM, et al. Predictive factors in chronic graftversus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med. 1983;98: Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: beneficial effect of a protective environment. N Engl J Med. 1983;308: Woodruff JM, Eltringham JR, Casey HW. Early secondary disease in the rhesus monkey, I: a comparative histopathologic study. Lab Invest. 1969;20: Woodruff JM, Butcher WI, Hellerstein LJ. Early secondary disease in rhesus monkey, II: electron microscopy of changes in mucous membrane and the external epithelia as demonstrated in the tongue and lip. Lab Invest. 1972;27: Slavin RE, Santos GW. The graft-versus-host reaction in man after bone marrow transplantation: pathology, pathogenesis, clinical features and implications. Clin Immunol Immunopathol. 1973;1: Woodruff JM, Hansen JA, Good RA, Santos GW, Slavin RE. The pathology of the graft-versus-host reaction (GvHR) in adults receiving bone marrow transplants. Transplant Proc. 1976;8: Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol.1977;89: Hymes SR, Farmer ER, Lewis PG, Tutschka PJ, Santos GW. Cutaneous graftversus-host reaction: prognostic features seen by light microscopy. J Am Acad Dermatol. 1985;12: Elliott CJ, Sloane JP, Sanderson KV, Vincent M, Shepherd V, Powles R. The histological diagnosis of cutaneous graft versus host disease: relationship of skin changes to marrow purging and other clinical variables. Histopathology. 1987; 11: Kohler S, Hendrickson MR, Chao NJ, Smoller BR. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol. 1997;21: Drijkoningen M, De Wolf-Peeters C, Tricot G, Degreef H, Desmet V. Druginduced skin reactions and cutaneous graft-versus-host reaction: a comparative immunohistochemical study. Blut. 1988;56: Sviland L, Oearson ADJ, Eastham EJ, Hamilton PJ, Proctor SJ, Malcom AJ. Histological features of skin and rectal biopsy specimens after autologous and allogeneic bone marrow transplantation. J Clin Pathol. 1988;41: Darmstadt GL, Donnenberg AD, Vogelsang GB, Farmer ER, Horn TD. Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease. J Invest Dermatol. 1992;99: Barksdale SK, Oberlender SA, Barnhill RL. Rush skin biopsy specimens in a tertiary medical center: diagnostic yield and clinical utility. J Am Acad Dermatol. 1998;38:
I graft-versus-host disease (GVHD) after allogeneic bone
Acute Upper Gastrointestinal Graft-Versus-Host Disease: Clinical Significance and Response to Immunosuppressive Therapy By Daniel J. Weisdorf, Dale C. Snover, Robert Haake, Wesley J. Miller, Philip B.
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More informationPoor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte Globulin Treatment
Biology of Blood and Marrow Transplantation 8:155-160 (2002) 2002 American Society for Blood and Marrow Transplantation ASBMT Poor Outcome in Steroid-Refractory Graft-Versus-Host Disease With Antithymocyte
More informationKEY WORDS: Allogeneic, Hematopoietic cell transplantation, Graft-versus-host disease, Immunosuppressants, Cyclosporine, Tacrolimus
A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells Yoshihiro Inamoto, 1
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationThe New England Journal of Medicine BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA
BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA JOHN A. HANSEN, M.D., THEODORE A. GOOLEY, PH.D., PAUL J. MARTIN, M.D., FREDERICK APPELBAUM, M.D., THOMAS R. CHAUNCEY,
More informationM Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, RM Lemoli, A Bonini, A Belardinelli, MR Motta, S Rizzi and S Tura
Bone Marrow Transplantation, (1998) 22, 27 32 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt High-dose busulfan and cyclophosphamide are an effective conditioning
More informationA substantially to the morbidity and mortality of allogeneic
A Retrospective Analysis of Therapy for Acute Graft-Versus-Host Disease: Initial Treatment By Paul J. Martin, Gary Schoch, Lloyd Fisher, Vera Byers, Claudio Anasetti, Frederick R. Appelbaum, Patrick G.
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationClinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes
Advances in Hematology Volume 2011, Article ID 601953, 8 pages doi:10.1155/2011/601953 Clinical Study Steroid-Refractory Acute GVHD: Predictors and Outcomes Jason R. Westin, 1 Rima M. Saliba, 1 Marcos
More informationTransplantation Program, University of Minnesota, Minneapolis, Minnesota
Biology of Blood and Marrow Transplantation 6:441-447 (2000) 2000 American Society for Blood and Marrow Transplantation ASBMT A Randomized Trial Comparing Prednisone With Antithymocyte Globulin/Prednisone
More informationGrover s disease: A case report.
320 Case report Thai J Dermatol, October-December 2011 ABSTRACT: Grover s disease: A case report. Supicha Chavanich MD, Praneet Sajjachareonpong MD. CHAVANICH C, SAJJACHAREONPONG P. GROVER S DISEASE: A
More informationClinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
Clinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation Reference: NHS England F01X08/01 1 Information Reader Box (IRB)
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationObjectives. Hematopoietic Stem Cell Transplant. Approaches to Transplant. Indications for HSCT. Define HSCT. Provide overview of HSCT process
Objectives Hematopoietic Stem Cell Transplant Karen Anderson, MN, RN, OCN University of Washington Medical Center Define HSCT Provide overview of HSCT process Discuss acute complications of HSCT Discuss
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationA High-Dose Pulse Steroid Regimen for Controlling Active Chronic Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation 7:495-502 (2001) 2001 American Society for Blood and Marrow Transplantation ASBMT A High-Dose Pulse Steroid Regimen for Controlling Active Chronic Graft-Versus-Host
More informationImproved prognosis for acquired aplastic anaemia
158 Department of Haematology and Oncology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK L A Pitcher I M Hann JPMEvans P Veys J M Chessells DKHWebb Correspondence to: Dr Webb.
More informationApproach to the Transplant Patient. Amy Musiek, MD AAD Annual Meeting 2018
Approach to the Transplant Patient Amy Musiek, MD AAD Annual Meeting 2018 Disclosures Actelion: speaker, advisory board, investigator Elorac: investigator Kyowa: investigator, advisory board Seattle genetics:
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationKavita Raj Consultant Haematologist KHP
Kavita Raj Consultant Haematologist KHP 1950s Billingham and Brent injection of spleen cells from adult mice into newborn mice Thickening and loss elasticity of skin, red soles, exfoliation, diarrhoea
More informationPre-Engraftment Syndrome after Double-Unit Cord Blood Transplantation: A Distinct Syndrome not Associated with Acute Graft-Versus-Host Disease
Pre-Engraftment Syndrome after Double-Unit Cord Blood Transplantation: A Distinct Syndrome not Associated with Acute Graft-Versus-Host Disease Kevin J. Patel, Robert D. Rice, Rebecca Hawke, Michelle Abboud,
More informationParacentral Corneal Melting in Four Patients With Chronic Graft-Versus-Host Disease
Paracentral Corneal Melting in Four Patients With Chronic Graft-Versus-Host Disease Neil Chungfat, MD, MEng 1,2 ; Jocelyn Rowe, MD 1,3 ; Neal P. Barney, MD 1 ; Sarah Nehls, MD 1 The authors have no financial
More informationTransplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén
More informationORIGINAL ARTICLE. Severe Acute Gastrointestinal Graft-vs-Host Disease. An Emerging Surgical Dilemma in Contemporary Cancer Care
ORIGINAL ARTICLE Severe Acute Gastrointestinal Graft-vs-Host Disease An Emerging Surgical Dilemma in Contemporary Cancer Care Jennifer L. Irani, MD; Corey S. Cutler, MD, MPH; Edward E. Whang, MD; Thomas
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationDEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
More informationStem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP
Stem Cells And The Future of Regenerative Medicine Dipnarine Maharaj, M. D., FACP The following potential conflict of interest relationships are germane to my presentation. Employment: South Florida Bone
More informationHematology and Oncology, The Cleveland Clinic, Cleveland, Ohio; 3 Department of Biostatistics, The Ohio State University Hospitals, Columbus, Ohio
Biology of Blood and Marrow Transplantation 12:61-67 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0004$32.00/0 doi:10.1016/j.bbmt.2005.06.004 High Disease Burden
More informationAllogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )
TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi
More information4/28/2016. Disclosure. Management of Pediatric Hematopoietic Stem-Cell Transplant Complications. Objectives - Technician. Objectives - Pharmacist
Disclosure Management of Pediatric Hematopoietic Stem-Cell Transplant Complications Jenna Bender has no actual or potential conflicts of interest to report Off-label use of medication will be discussed
More informationHepatitis-Associated Aplastic Anemia. Kazuko KUDO and Seiji KOJIMA Department of Pediatrics, Nagoya University Graduate School of Medicine
Hepatitis-Associated Aplastic Anemia Kazuko KUDO and Seiji KOJIMA Department of Pediatrics, Nagoya University Graduate School of Medicine Abstract We retrospectively analysed the clinical outcome of 85
More informationSKIN CANCER AFTER HSCT
SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationASBMT and Marrow Transplantation
Biol Blood Marrow Transplant 19 (2013) 661e675 Brief Articles Improved Survival over the Last Decade in Pediatric Patients Requiring Dialysis after Hematopoietic Cell Transplantation American Society for
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationIntensified conditioning regimen in bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
Bone Marrow Transplantation, (1998) 22, 1029 1033 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 http://www.stockton-press.co.uk/bmt Intensified conditioning regimen in bone marrow transplantation
More informationG. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728
G. Socié, MD, PhD Hematology Transplantation Hospital Saint Louis Paris University Paris Denis Diderot & INSERM U728 16:00-17:30 Session 7 GvHD Prevention by T-Cell Modulation Is photopheresis treatment
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationTransplantation Immunology
Transplantation Immunology Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation Children s Hospital New York Presbyterian
More informationTransplantation Immunology
Transplantation Immunology MHC Restricted Allograft Rejection Mitchell S. Cairo, MD Professor of Pediatrics, Medicine and Pathology Chief, Division, Pediatric Hematology & Blood & Marrow Transplantation
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationVOLUME 46 ㆍ NUMBER 3 ㆍ September 2011
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Clinical significance of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in acute graft-versus-host
More informationNatasha Ali, 1 Salman Naseem Adil, 1 Mohammad Usman Shaikh, 1 and Nehal Masood Introduction
ISRN Hematology Volume 2013, Article ID 232519, 6 pages http://dx.doi.org/10.1155/2013/232519 Clinical Study Frequency and Outcome of Graft versus Host Disease after Stem Cell Transplantation: A Six-Year
More informationFailure-free survival after initial systemic treatment of chronic graft-versus-host disease
From www.bloodjournal.org by guest on November 19, 2014. For personal use only. 2014 124: 1363-1371 doi:10.1182/blood-2014-03-563544 originally published online May 29, 2014 Failure-free survival after
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More information2/4/14. Disclosure. Learning Objective
Utilizing Intravenous Busulfan Pharmacokinetics for Dosing Busulfan And Fludarabine Conditioning Regimens In Institutions Where The Capability Of Doing Pharmacokinetics Is Not Present Shaily Arora, PharmD
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationKEY WORDS: Hematopoietic cell transplantation, Pulmonary complications
Allogeneic Peripheral Blood Stem Cell Transplantation Significantly Increases Risk of Chronic Graft-versus-Host Disease of Lung Compared with Bone Marrow Transplantation Naheed Alam, 1 Theodore K. Marras,
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationAcute GVHD. ESH-EBMT 2009 Latimer A. Devergie
Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier
More informationMyelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers
(23) 32, 35 4 & 23 Nature Publishing Group All rights reserved 268-3369/3 $25. www.nature.com/bmt Myelofibrosis Stem cell transplantation for myelofibrosis: a report from two Canadian centers A Daly 1,
More informationThe clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation
Bone Marrow Transplantation, (1999) 23, 45 51 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt The clinical utility of CMV surveillance cultures and antigenemia
More informationBB&MT. KEY WORDS Reduced-intensity regimen Allogeneic hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 9:189 197 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0903-0007$30.00/0 doi: 10.1053/bbmt.2003.50012 Lowered-Intensity Preparative
More informationStem cell transplantation. Dr Mohammed Karodia NHLS & UP
Stem cell transplantation Dr Mohammed Karodia NHLS & UP The use of haemopoeitic stem cells from a donor harvested from peripheral blood or bone marrow, to repopulate recipient bone marrow. Allogeneic From
More informationDiagnostic features of transfusion associated graft
JT Clin Pathol 1994;47:541-546 Diagnostic features of transfusion associated graft versus host disease 541 Department of Pathology, University of Newcastle Upon Tyne, Royal Victoria Infirmary, Newcastle
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More information4100: Cellular Therapy Essential Data Follow-Up Form
4100: Cellular Therapy Essential Data Follow-Up Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: Visit: 100 day 6 months 1 year 2 years >2 years, Specify:
More informationEvaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationEarly cyclosporine taper in high-risk sibling allogeneic bone marrow transplants
Bone Marrow Transplantation, (1997) 2, 773 777 1997 Stockton Press All rights reserved 268 3369/97 $12. Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants R Abraham, J Szer,
More informationIN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL
TREATMENT OF ADENOVIRUS (AdV) INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT PATIENTS WITH BRINCIDOFOVIR: FINAL 36 WEEK RESULTS FROM THE ADVISE TRIAL Vinod K. Prasad, MD, FRCP 1, Genovefa A. Papanicolaou,
More informationBone Marrow Transplantation: Current Results in Leukemia
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 55 (1982), 477-485 Bone Marrow Transplantation: Current Results in Leukemia GEORGE W. SANTOS, M.D. Professor of Oncology and Medicine, Oncology Center, Johns Hopkins
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationTransplantation Immunology Booklet C
Booklet C Pretest Correct Answers 3. (C) is correct. One of the major barriers to successful hematopoietic stem cell transplantation is the antigens coded for by the major histocompatibility gene complex.
More informationIntracellular staining of granzyme B and perforin for diagnosis of acute graft-versus-host disease
Jichi Medical University Journal Original Article Intracellular staining of granzyme B and perforin for diagnosis of acute graft-versus-host disease Haruko Matsu, Katsutoshi Ozaki, Raine Tatara, Satoko
More informationHematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
More informationUse of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow
Bone Marrow Transplantation, (1999) 23, 889 893 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Use of a five-agent GVHD prevention regimen in recipients
More informationLow-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation
Biology of Blood and Marrow Transplantation 9:453-459 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0907-0005$30.00/0 doi:10.1016/s1083-8791(03)00139-3 Low-Dose Total Body
More informationHematopoietic Cell Transplantation for Myelofibrosis. Outline
Hematopoietic Cell Transplantation for Myelofibrosis H.Joachim Deeg MD Fred Hutchinson Cancer Research Center & University of Washington, Seattle WA Great Debates, NY, 4/28/2012 Outline Rationale for hematopoietic
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationCLINICAL REPORT. (Accepted December 4, 2003.) Acta Derm Venereol 2004; 84:
Acta Derm Venereol 2004; 84: 296 301 CLINICAL REPORT Clinical Manifestations of Cutaneous Graft-versus-host Disease after Allogeneic Haematopoietic Cell Transplantation: Long-term Follow-up Results in
More information& 2005 Nature Publishing Group All rights reserved /05 $
(2005) 35, 515 519 & 2005 Nature Publishing Group All rights reserved 0268-3369/05 $30.00 www.nature.com/bmt Graft-versus-host disease Medium dose long-wavelength ultraviolet A () phototherapy for the
More informationBRIEF ARTICLE. Coralia N. Mihu, 1 Jenifer Schaub, 1 Sandra Kesh, 1 Ann Jakubowski, 2 Kent Sepkowitz, 1 Eric G. Pamer, 1 Genovefa A.
BRIEF ARTICLE Risk Factors for Late Staphylococcus Aureus Bacteremia after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Institution, Nested Case-Controlled Study Coralia N. Mihu, 1 Jenifer
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationIntestinal agvhd and infection after hematopoietic stem cell transplantation
e-issn 1643-3750 DOI: 10.12659/MSM.889408 Received: 2013.05.28 Accepted: 2013.08.07 Published: 2013.09.30 Intestinal agvhd and infection after hematopoietic stem cell transplantation Authors Contribution:
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationCord Blood Stem Cell Banking and Transplantation
Cord Blood Stem Cell Banking and Transplantation JOHN W. ADAMSON New York Blood Center, New York, New York, USA Key Words. Cord blood Stem cells Cord blood banking Cord blood transplantation. Cord blood.stern
More informationSickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
More informationBONE MARROW TRANSPLANTATION - PAST, PRESENT AND FUTURE
BONE MARROW TRANSPLANTATION - PAST, PRESENT AND FUTURE Nobel Lecture, December 8, 1990 by E. DONNALL THOMAS The Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington,
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationSylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.
Bone Marrow Research Volume 2012, Article ID 873695, 5 pages doi:10.1155/2012/873695 Clinical Study Both Optimal Matching and Procedure Duration Influence Survival of Patients after Unrelated Donor Hematopoietic
More informationTRANSPLANTATION OF PERIPHERAL-BLOOD CELLS IN PATIENTS WITH HEMATOLOGIC CANCERS
TRANSPLANTATION OF BLOOD CELLS IN PATIENTS WITH HEMATOLOGIC CANCERS TRANSPLANTATION OF AS COMPARED WITH BLOOD CELLS FROM HLA-IDENTICAL RELATIVES IN PATIENTS WITH HEMATOLOGIC CANCERS WILLIAM I. BENSINGER,
More informationHIV and transplant: obstacles and opportunities
HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part
More information